Molecularly Guided Chemotherapy Boosts Survival in Early NSCLC A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.

Chemo gets clever: A molecular test helps pinpoint which early-stage NSCLC patients will benefit most from chemo; boosting survival & precision. #TCSC #LungCancer #NSCLC #PersonalisedMedicine #OncologyBreakthrough #CancerTreatment #AdjuvantChemo #MolecularAssay

www.targetedonc.com/view/molecul...